SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

   Biotech / MedicalImmunomedics (IMMU) - moderated


Previous 10 Next 10 
To: idahoranch1 who wrote (45903)4/25/2018 1:24:21 PM
From: erippetoe
2 Recommendations   of 58344
 



HR+/HER2- breast cancer is the most common form of breast cancer. This type accounts for more than 70% of all breast cancers.

advancedbreastcancercommunity.org

So yes a fairly large population.




Thanks!




Share RecommendKeepReplyMark as Last ReadRead Replies (1)


From: erippetoe4/25/2018 1:25:27 PM
   of 58344
 
Do you think we can anticipate that the data is good since it's an oral presentation?

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: patlawche11 who wrote (45901)4/25/2018 2:32:02 PM
From: patlawche11
3 Recommendations   of 58344
 
FWIW...IMMU132 status changed today from active, recruiting to active, not recruiting for Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers. So...I would imagine they are currently not treating new/additional patients for UC, as well as for other indications in this trial.

clinicaltrials.gov

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: erippetoe who wrote (45905)4/25/2018 2:42:40 PM
From: idahoranch1
4 Recommendations   of 58344
 
ASCO Oral presentations:

ORAL ABSTRACT SESSIONSThis type of session includes 12-minute presentations of abstracts representing important clinical and translational research findings by topic category. Presenting authors should use PowerPoint slides to accompany their oral presentation. Experts in the field (discussants) are chosen to provide comprehensive 12-minute themed discussions of the findings from predetermined abstracts. All speakers will participate in a question-and-answer panel in the session. The duration of this type of session is 3 hours.

Share RecommendKeepReplyMark as Last Read


To: erippetoe who wrote (45904)4/25/2018 3:02:23 PM
From: weatherproof
4 Recommendations   of 58344
 
For comparison, the projected revenue numbers have largely been predicated on TNBC, which only represents about 15% of breast cancers.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: weatherproof who wrote (45908)4/25/2018 3:23:55 PM
From: erippetoe
   of 58344
 
Interesting, thanks! This link provides a pretty good summary of current treatments and response rates, PFS, etc. sciencedirect.com
although there certainly may be better ones, this was the best I could find after a quick search.

Share RecommendKeepReplyMark as Last Read


To: idahoranch1 who wrote (45903)4/25/2018 5:02:06 PM
From: idahoranch1
14 Recommendations   of 58344
 
A while back I suggested that when Michael Pehl commented in a CC a few months ago that they were evaluating data from over 70 patients with erMBC, that maybe they pulled all those patients from all the breast cancer patients, including the TNBC patients, to get this data. It was point out to me that TNBC patients are negative HR and in fact are negative 3 primary targets.
So the data we will get in the oral presentation appears to be to be from over 70 patients in the basket trial but they were recruited to investigate 132’s efficacy in HR+MBC. This makes this higher quality data than I was anticipating.
The clock is ticking towards some milestones. The abstracts on May 16th, AA filing shortly after and presentation of HR+ MBC Sunday June 3rd and investor meeting that night as well.

Share RecommendKeepReplyMark as Last Read


From: drtom12344/26/2018 5:30:01 AM
19 Recommendations   of 58344
 
I think it's important that we understand how important this ASCO presentation is. This year, around 266,000 women in the US will be diagnosed with invasive breast cancer. Only 15% of those will have TNBC, but two thirds of breast cancer is hormone receptor positive. Even if you assume that SG will be used only in cases failing standard therapy, use of SG in this patient population would dramatically increase the potential patient population. And that's just in the U.S; around the world, over 1.7 million women will be diagnosed with breast cancer every year, meaning over 1 million women with hormone receptor positive invasive breast cancer will be potential patients for SG.

Moreover, the fact that this was given an oral presentation spot rather than a simple poster presentation means the ASCO organizers feel that it is a significant piece of research, and needs a larger audience.

If the data is good, and presumably it is based on Immunomedics advertising it with an investor presentation at ASCO, then the company could see large scale off label use after it gets TNBC accelerated approval, and while confirmatory studies are being done.

Basically, "silly" valuation of the company may be closer than previously thought.

Now bring on urothelial breakthrough status!

Share RecommendKeepReplyMark as Last Read


From: erippetoe4/26/2018 9:38:07 AM
1 Recommendation   of 58344
 
Short number at 28,384,688 up 10,103 from last time.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: erippetoe who wrote (45912)4/26/2018 1:04:09 PM
From: Dietman
1 Recommendation   of 58344
 
I think I may have asked this before but what the hell...We are all just waiting for the upcoming catalysts as patiently as possible.
What are we to glean from short numbers.... So far, from the answers that have been posted is..nobody seems to know... If this is so....should we really care what that number is?? And erippetoe...I mean no disrespect...I am trying to understand.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)
Previous 10 Next 10